Cancer and Thrombosis: New Treatments, New Challenges.
Anders Erik Astrup DahmPublished in: Medical sciences (Basel, Switzerland) (2021)
The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with difficult decisions regarding DOAC treatment: Which patients cannot use DOACs? Should incidental VTE be treated similar to symptomatic VTE? Is it safe to give DOACs to patients with gastrointestinal or urogenital cancers? How about drug-drug interactions? Should all cancer patients receive thromboprophylaxis? Is arterial thrombosis a problem? The current article reviews the available literature regarding these questions and aims to provide practical solutions based on data from the clinical trials and new guidelines.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- clinical trial
- end stage renal disease
- pulmonary embolism
- newly diagnosed
- systematic review
- chronic kidney disease
- palliative care
- ejection fraction
- peritoneal dialysis
- squamous cell carcinoma
- prognostic factors
- combination therapy
- replacement therapy
- clinical practice
- study protocol
- childhood cancer